182 filings
Page 2 of 10
NT 10-Q
lxkqtsdcene3pfwvp7i
16 May 22
Notice of late quarterly filing
4:35pm
8-K
x9a63yjexck7 d6iy5s
11 Apr 22
Unregistered Sales of Equity Securities
5:11pm
NT 10-K
1r31pbr pptlvooxt
30 Dec 21
Notice of late annual filing
1:49pm
8-K
xi1z5qynhljfk70y7
12 Oct 21
Regulation FD Disclosure
8:27am
8-K
6z5lmslfsqqlgp15
4 Oct 21
Regulation FD Disclosure
8:48am
8-K
62v7sovc
20 Sep 21
Multiple Sclerosis Drug Development Information September 2021
8:16am
NT 10-Q
pdr67
16 Aug 21
Notice of late quarterly filing
4:33pm
NT 10-Q
6gy87tk5u0y6o yq5
17 May 21
Notice of late quarterly filing
11:37am
8-K
4poqlnawp e6ztpz
6 May 21
AngioSoma, Inc. Adds Brooke Greenwald As Chief Marketing Officer
5:27pm
8-K
trpx1060uvs
5 May 21
Regulation FD Disclosure
4:17pm
8-K
sic8n cslqszc
16 Apr 21
AngioSoma, Inc. Is Pleased to Welcome William Farley to Its Board of Directors
4:20pm
8-K
r2rs0g
5 Mar 21
Departure of Directors or Certain Officers
8:49am
8-K
y3mb nt73772byq
25 Feb 21
Angiosoma and its Subsidiary Somaceuticals Announce Amended and Restated Execution of Global License for Multiple Sclerosis Patent
5:30pm
8-K
39j1 u45oizi6jaa3
22 Dec 20
Regulation FD Disclosure
5:14pm
8-K
zvmxr 2yz
9 Dec 20
SomaCeuticals Moving Forward With Treatment of Multiple Sclerosis
12:00am